• Earlier in May 2026, Mirum Pharmaceuticals completed a US$600,000,000 zero-coupon senior unsecured convertible note offering due June 1, 2032, while also reporting a quarterly net loss of US$790.16 million and raising 2026 net product sales guidance to US$660 million–US$680 million.
• The company also reported that its VISTAS Phase 2b trial of volixibat in primary sclerosing cholangitis met its primary endpoint, reinforcing the potential for the drug to address an area with no approved PSC therapies and supporting plans for a U.S. FDA pre-NDA meeting and an NDA submission in the second half of 2026.
• We’ll now examine how the positive VISTAS Phase 2b volixibat results may reshape Mirum’s rare-disease growth narrative and pipeline outlook.

The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 17 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.

Mirum Pharmaceuticals Investment Narrative Recap

To own Mirum Pharmaceuticals, you have to believe its rare-disease portfolio can broaden beyond Livmarli, with volixibat in PSC emerging as a second key pillar. The positive VISTAS Phase 2b readout directly supports that thesis and appears to be the most important near term catalyst, while the sharp US$790.16 million quarterly net loss and ongoing cash burn highlight financing and execution risk around getting volixibat and other assets to market.

The recent US$600,000,000 zero coupon senior unsecured convertible note due 2032 stands out here, as it materially extends Mirum’s funding runway while potentially diluting shareholders over time. Against a backdrop of raised 2026 net product sales guidance to US$660 million to US$680 million, it reinforces how dependent the story still is on converting pipeline milestones like VISTAS, VANTAGE and AZURE into durable commercial products...

Mirum Pharmaceuticals' narrative projects $978.8 million revenue and $134.8 million earnings by 2029.

Uncover how Mirum Pharmaceuticals' forecasts yield a $129.73 fair value, a 27% upside to its current price.

Exploring Other Perspectives

Some of the lowest estimate analysts were expecting about US$713 million of revenue and only US$23 million of earnings by 2028, so compared with the more upbeat PSC-driven thesis, they are building in much tougher assumptions around pricing pressure and regulatory risk that could look very different after the VISTAS news.

Explore 3 other fair value estimates on Mirum Pharmaceuticals - why the stock might be worth 7% less than the current price!

Decide For Yourself

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Mirum Pharmaceuticals research is our analysis highlighting 3 key rewards and 2 important warning signs that could impact your investment decision.
• Our free Mirum Pharmaceuticals research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Mirum Pharmaceuticals' overall financial health at a glance.

Searching For A Fresh Perspective?

Don't miss your shot at the next 10-bagger. Our latest stock picks just dropped:

• Uncover the next big thing with 28 elite penny stocks that balance risk and reward.
• The future of work is here. Discover the 34 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
• This technology could replace computers: discover 26 stocks that are working to make quantum computing a reality.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.